{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:48:34Z","timestamp":1776988114073,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST104-2320-B-038-009; MOST105-2320-B-038-006; MOST 104-2314-B-038 -046 -MY3"],"award-info":[{"award-number":["MOST104-2320-B-038-009; MOST105-2320-B-038-006; MOST 104-2314-B-038 -046 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12672-018-0334-9","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T01:46:25Z","timestamp":1532051185000},"page":"349-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers"],"prefix":"10.1007","volume":"9","author":[{"given":"Andr\u00e9 Wendindond\u00e9","family":"Nana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen SH","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tang","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Mu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yih","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Jung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Incerpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleck","family":"Hercbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leroy F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Whang-Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-6419","authenticated-orcid":false,"given":"Hung-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"issue":"3","key":"334_CR1","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers (Basel) 6(3):1769\u20131792","journal-title":"Cancers (Basel)"},{"key":"334_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","volume":"75","author":"P Nordlund","year":"2006","unstructured":"Nordlund P, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681\u2013706","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"334_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1365-2559.2010.03725.x","volume":"57","author":"T Morikawa","year":"2010","unstructured":"Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M (2010) Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57(6):885\u2013892","journal-title":"Histopathology"},{"issue":"12","key":"334_CR4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.humpath.2010.06.001","volume":"41","author":"T Morikawa","year":"2010","unstructured":"Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M (2010) Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol 41(12):1742\u20131748","journal-title":"Hum Pathol"},{"key":"334_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/1471-2407-14-664","volume":"14","author":"H Zhang","year":"2014","unstructured":"Zhang H, Liu X, Warden CD, Huang Y, Loera S, Xue L, Zhang S, Chu P, Zheng S, Yen Y (2014) Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer 14:664","journal-title":"BMC Cancer"},{"issue":"9","key":"334_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1042\/CS20120240","volume":"124","author":"X Liu","year":"2013","unstructured":"Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, Nelson RA, Zhou B, Zhou L, Chu P, Zhang S, Zheng S, Yen Y (2013) Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond) 124(9):567\u2013578","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"334_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/1541-7786.MCR-13-0219","volume":"12","author":"KN Shah","year":"2014","unstructured":"Shah KN, Mehta KR, Peterson D, Evangelista M, Livesey JC, Faridi JS (2014) AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res 12(3):394\u2013407","journal-title":"Mol Cancer Res"},{"issue":"8","key":"334_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/sj.onc.1207272","volume":"23","author":"MS Duxbury","year":"2003","unstructured":"Duxbury MS et al (2003) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23(8):1539\u20131548","journal-title":"Oncogene"},{"issue":"3","key":"334_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jphs.2015.01.006","volume":"127","author":"K Minami","year":"2015","unstructured":"Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K, Tsujikawa K, Chijiiwa K, Yamada K, Akiyama SI, P\u00e9rez-Torras S, Pastor-Anglada M, Furukawa T, Yasuo T (2015) Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J Pharmacol Sci 127(3):319\u2013325","journal-title":"J Pharmacol Sci"},{"key":"334_CR10","first-page":"240","volume":"5","author":"PJ Davis","year":"2014","unstructured":"Davis PJ et al (2014) Cancer cell gene expression modulated from plasma membrane integrin \u03b1v\u03b23 by thyroid hormone and nanoparticulate tetrac. Front Endocrinol (Lausanne) 5:240","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"334_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12672-013-0156-8","volume":"4","author":"PJ Davis","year":"2013","unstructured":"Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY (2013) Small molecule hormone or hormone-like ligands of integrin \u03b1v\u03b23: implications for cancer cell behavior. Horm Cancer 4(6):335\u2013342","journal-title":"Horm Cancer"},{"issue":"10","key":"334_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1096\/fj.06-5743fje","volume":"20","author":"HY Lin","year":"2006","unstructured":"Lin HY, Lansing L, Merillon JM, Davis FB, Tang HY, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, Bergh J, Quackenbush S, Davis PJ (2006) Integrin \u03b1v\u03b23 contains a receptor site for resveratrol. FASEB J 20(10):1742\u20131744","journal-title":"FASEB J"},{"issue":"3","key":"334_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cphy.c150035","volume":"6","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chin YT, Yang YC, Lai HY, Wang-Peng J, Liu LF, Tang HY, Davis PJ (2016) Thyroid hormone, cancer, and apoptosis. Compr Physiol 6(3):1221\u20131237","journal-title":"Compr Physiol"},{"key":"334_CR14","first-page":"156","volume-title":"Horm Cancer","author":"YS Lee","year":"2018","unstructured":"Lee YS, Chin YT, Shih YJ, Nana AW, Chen YR, Wu HC, Yang YCSH, Lin HY, Davis PJ (2018) Thyroid hormone promotes \u03b2-catenin activation and cell proliferation in colorectal cancer. In: Horm Cancer, vol 9, pp 156\u2013165"},{"key":"334_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.steroids.2016.05.006","volume":"114","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chin YT, Nana AW, Shih YJ, Lai HY, Tang HY, Leinung M, Mousa SA, Davis PJ (2016) Actions of l-thyroxine and nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. Steroids 114:59\u201367","journal-title":"Steroids"},{"issue":"3","key":"334_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1530\/ERC-17-0450","volume":"25","author":"AW Nana","year":"2018","unstructured":"Nana AW, Chin YT, Lin CY, Ho Y, Bennett JA, Shih YJ, Chen YR, Changou CA, Pedersen JZ, Incerpi S, Liu LF, Whang-Peng J, Fu E, Li WS, Mousa SA, Lin HY, Davis PJ (2018) Tetrac downregulates \u03b2-catenin and HMGA2 to promote the effect of resveratrol in colon cancer. Endocr Relat Cancer 25(3):279\u2013293","journal-title":"Endocr Relat Cancer"},{"key":"334_CR17","unstructured":"Mousa, S.A., et al., Nano-diamino-tetrac (Nanotetrac), a thyroid hormone antagonist at integrin \u03b1v\u03b23, causes necrosis via anti-angiogenesis and induces apoptosis in human glioblastoma xenografts, in Late-Breaking Tumor Biology II (posters). 2016, Endocrine Society. p. LBSAT-03-LBSAT-03"},{"issue":"3","key":"334_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12672-017-0293-6","volume":"8","author":"T Sudha","year":"2017","unstructured":"Sudha T, Bharali DJ, Sell S, Darwish NHE, Davis PJ, Mousa SA (2017) Nanoparticulate tetrac inhibits growth and vascularity of glioblastoma xenografts. Horm Cancer 8(3):157\u2013165","journal-title":"Horm Cancer"},{"issue":"2","key":"334_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/thy.2007.0248","volume":"18","author":"M Moreno","year":"2008","unstructured":"Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F (2008) Metabolic effects of thyroid hormone derivatives. Thyroid 18(2):239\u2013253","journal-title":"Thyroid"},{"issue":"12","key":"334_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2217\/nnm.12.200","volume":"8","author":"DJ Bharali","year":"2013","unstructured":"Bharali DJ, Yalcin M, Davis PJ, Mousa SA (2013) Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) 8(12):1943\u20131954","journal-title":"Nanomedicine (Lond)"},{"key":"334_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.steroids.2016.03.006","volume":"111","author":"YS Lee","year":"2016","unstructured":"Lee YS, Chin YT, Yang YCSH, Wei PL, Wu HC, Shih A, Lu YT, Pedersen JZ, Incerpi S, Liu LF, Lin HY, Davis PJ (2016) The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. Steroids 111:63\u201370","journal-title":"Steroids"},{"issue":"34","key":"334_CR22","doi-asserted-by":"publisher","first-page":"35866","DOI":"10.18632\/oncotarget.5482","volume":"6","author":"YT Chin","year":"2015","unstructured":"Chin YT, Yang SH, Chang TC, Changou CA, Lai HY, Fu E, HuangFu W, Davis PJ, Lin HY, Liu LF (2015) Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ER\u03b1 status. Oncotarget 6(34):35866\u201335879","journal-title":"Oncotarget"},{"key":"334_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1749-6632.2010.05846.x","volume":"1215","author":"HY Lin","year":"2011","unstructured":"Lin HY, Tang HY, Davis FB, Davis PJ (2011) Resveratrol and apoptosis. Ann N Y Acad Sci 1215:79\u201388","journal-title":"Ann N Y Acad Sci"},{"issue":"17","key":"334_CR24","doi-asserted-by":"publisher","first-page":"14735","DOI":"10.18632\/oncotarget.4023","volume":"6","author":"HY Lin","year":"2015","unstructured":"Lin HY, Glinsky GV, Mousa SA, Davis PJ (2015) Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6(17):14735\u201314743","journal-title":"Oncotarget"},{"issue":"2","key":"334_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.steroids.2006.11.014","volume":"72","author":"HY Lin","year":"2007","unstructured":"Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, Davis FB (2007) Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72(2):180\u2013187","journal-title":"Steroids"},{"issue":"10","key":"334_CR26","first-page":"3825","volume":"29","author":"M Yalcin","year":"2009","unstructured":"Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA (2009) Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 29(10):3825\u20133831","journal-title":"Anticancer Res"},{"issue":"37","key":"334_CR27","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1038\/sj.onc.1203774","volume":"19","author":"K Nakano","year":"2000","unstructured":"Nakano K, B\u00e1lint \u00c9, Ashcroft M, Vousden KH (2000) A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19(37):4283\u20134289","journal-title":"Oncogene"},{"issue":"6773","key":"334_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/35003506","volume":"404","author":"H Tanaka","year":"2000","unstructured":"Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404(6773):42\u201349","journal-title":"Nature"},{"issue":"7","key":"334_CR29","first-page":"2535","volume":"31","author":"Y Yoshida","year":"2011","unstructured":"Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S (2011) KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res 31(7):2535\u20132539","journal-title":"Anticancer Res"},{"issue":"1","key":"334_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.59566\/IJBS.2009.5001","volume":"5","author":"A Amin","year":"2009","unstructured":"Amin A et al (2009) Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci 5(1):1\u201311","journal-title":"Int J Biomed Sci"},{"issue":"2","key":"334_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3892\/or.2012.2151","volume":"29","author":"EJ Gweon","year":"2013","unstructured":"Gweon EJ, Kim SJ (2013) Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells. Oncol Rep 29(2):826\u2013834","journal-title":"Oncol Rep"},{"issue":"9","key":"334_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/carcin\/bgi104","volume":"26","author":"M Kim","year":"2005","unstructured":"Kim M, Murakami A, Kawabata K, Ohigashi H (2005) (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1\/2 pathway in HT-29 human colorectal cancer cells. Carcinogenesis 26(9):1553\u20131562","journal-title":"Carcinogenesis"},{"issue":"5307","key":"334_CR33","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","volume":"275","author":"PJ Morin","year":"1997","unstructured":"Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of \u03b2-catenin-Tcf signaling in colon cancer by mutations in \u03b2-catenin or APC. Science 275(5307):1787\u20131790","journal-title":"Science"},{"key":"334_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"The Cancer Genome Atlas, N","year":"2012","unstructured":"The Cancer Genome Atlas, N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330\u2013337","journal-title":"Nature"},{"issue":"6","key":"334_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.oraloncology.2008.07.005","volume":"45","author":"S Yanamoto","year":"2009","unstructured":"Yanamoto S, Kawasaki G, Yamada SI, Yoshitomi I, Yoshida H, Mizuno A (2009) Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin\/\u03b2-catenin pathway. Oral Oncol 45(6):521\u2013525","journal-title":"Oral Oncol"},{"issue":"1","key":"334_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/carcin\/bgm239","volume":"29","author":"HY Lin","year":"2008","unstructured":"Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, Sun M, Hercbergs A, Davis FB, Davis PJ (2008) Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 29(1):62\u201369","journal-title":"Carcinogenesis"},{"issue":"5","key":"334_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-17-0376","volume":"25","author":"YT Chin","year":"2018","unstructured":"Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, Yang YCSH, Hsieh MT, Hercbergs A, Davis PJ, Shih YJ, Lin HY (2018) Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocr Relat Cancer 25(5):533\u2013545","journal-title":"Endocr Relat Cancer"},{"key":"334_CR38","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2147\/OTT.S67393","volume":"7","author":"PJ Davis","year":"2014","unstructured":"Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Hercbergs A, Leith JT, Luidens MK, Ashur-Fabian O, Incerpi S, Mousa SA (2014) Nanotetrac targets integrin \u03b1v\u03b23 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther 7:1619\u20131624","journal-title":"Onco Targets Ther"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-018-0334-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-018-0334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-018-0334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T12:24:28Z","timestamp":1720441468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-018-0334-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1007\/s12672-018-0334-9","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,20]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Co-author Paul J. Davis is co-inventor of Nanotetrac, a nanoparticulate analog of tetrac. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}